市場調查報告書
商品編碼
1090214
RNA 療法的全球市場:增長機會Global RNA Therapeutics Growth Opportunities |
核酸療法的科學進步正在對全球生物製藥行業產生重大影響。 RNA(核糖核酸)治療市場有望取得重大臨床進展,因為它針對“無法治愈”的途徑。對技術優勢的日益增長的需求以及建立臨床上優越的 RNA 療法組合以提高競爭力的需求預計將促進 RNA 療法行業利益相關者之間的戰略夥伴關係。
本報告研究和分析全球 RNA 治療市場,並提供有關戰略必要因素、驅動因素、限制因素、主要趨勢、盈利預測、競爭環境、增長機會等方面的信息。
Future Growth Potential Driven by Co-Development Programs and Robust Clinical Trials for Diverse Disease Areas
Scientific advancements in nucleic acid-based therapies have significantly impacted the global biopharmaceutical industry. The ribonucleic acid (RNA) therapeutics market is expected to witness remarkable clinical progress as therapies target "undruggable" pathways. Technologically advanced platforms are integrated into RNA therapeutics bioprocessing to overcome stability issues. Technological advantages, coupled with the growing need to build clinically superior portfolios in RNA therapeutics for a competitive edge, are anticipated to drive strategic partnerships among stakeholders in the RNA therapeutics industry.
Spurred by the COVID-19 pandemic, biopharmaceutical companies are likely to prioritize microRNA, small interfering RNA, and antisense oligonucleotides as promising therapeutic modalities during the forecast period. Midsize and large companies have ramped up the production of starting materials and the final formulation of RNA therapeutics, which is likely to propel stakeholders to seek synergistic partnerships. In the industry's transition to personalized therapeutics, RNA developers are capitalizing on the high precision of RNA to treat untapped chronic disease areas such as cystic fibrosis, solid tumors, and spinal muscular atrophy. They engage in co-development programs to improve the stability profile of RNA therapeutics by optimizing drug delivery carriers, such as lipid nanoparticles.
Scaling up the production of starting materials, including plasmid DNA, oligonucleotides, and delivery materials, to ensure continuous manufacturing is anticipated to reduce the operational timeframe of RNA therapeutics production. Technology transfer and the outsourcing of crucial operations to contract development and manufacturing organizations (CDMO) catalyze the development of cost-effective and efficient models for RNA therapeutics.
This Frost & Sullivan research service provides an overview of the global RNA therapeutics industry from 2021 to 2027, including emerging trends, growth drivers, and growth opportunities.
The research service highlights the following: